VIDEO: Declining rate of HPV vaccination in adolescents

Article

Dr Anne Schuchat, Assistant Surgeon General and Director of the Centers for Disease Control and Prevention's (CDC) National Center for Immunization and Respiratory Diseases, discusses the recent CDC report on declining humanpapillomavirus vaccine rates in adolescents.

Dr Anne Schuchat, Assistant Surgeon General and Director of the Centers for Disease Control and Prevention's (CDC) National Center for Immunization and Respiratory Diseases, discusses the recent CDC report on declining humanpapillomavirus vaccine rates in adolescents.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Tina Tan, MD
Robert Frenck, MD
Importance of maternal influenza vaccination recommendations
Related Content
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD

Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD

Octavio Ramilo, MD
June 20th 2025
Article

Octavio Ramilo, MD, joins us once again to discuss potential benefits of RSV vaccination beyond disease prevention, and to explain how to speak with patients about vaccines and uptake.

What's going on with polio, monkeypox, and COVID-19

What's going on with polio, monkeypox, and COVID-19

Miranda Hester
August 19th 2022
Podcast

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

FDA approves clesrovimab to protect infants during first RSV season | Image Credit: Contemporary Pediatrics

FDA approves clesrovimab to protect infants during first RSV season

Joshua Fitch, Senior Editor
June 9th 2025
Article

The BLA for clesrovimab was based on results demonstrated in the phase 2b/3 CLEVER trial among healthy pre-term and full-term infants.

What Omicron could mean for the pandemic

What Omicron could mean for the pandemic

Miranda Hester
January 7th 2022
Podcast

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

Expert reactions to new COVID-19 vaccine policies

Expert reactions to new COVID-19 vaccine policies

Joshua Fitch, Senior Editor
May 30th 2025
Article

Federal health agencies have adjusted COVID vaccine guidance, potentially changing eligibility and access for pediatric patients. Experts respond in this article.

Nirsevimab demonstrates sustained efficacy in reducing RSV hospitalizations through 6 months | Image Credit: © Peter Hansen - © Peter Hansen - stock.adobe.com.

Nirsevimab demonstrates sustained efficacy in reducing RSV hospitalizations through 6 months

Joshua Fitch, Senior Editor
May 29th 2025
Article

New phase 3b durability data revealed nirsevimab reduced RSV hospitalizations in infants by 82.7% through 180 days vs no intervention.

© 2025 MJH Life Sciences

All rights reserved.